Androgen receptor antagonists can result in changes in uptake of flotufolastat F-18 in prostate cancer. Effect on POSLUMA PET performance not established.
Source: NLP:flotufolastat f-18
Flotufolastat F-18 Interactions
Brand names: Posluma
Radioactive Diagnostic Agent · Positron Emitting Activity
Route: Intravenous
Contraindications
4 CONTRAINDICATIONS None. None. ( 4 )
Pregnancy & Breastfeeding
8.1 Pregnancy Risk Summary POSLUMA is not indicated for use in females. There are no available data on the use of POSLUMA in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Animal reproduction studies have not been conducted with flotufolastat F 18. Radioactive drugs, including POSLUMA, have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose.
2 interactions on record
ADT can result in changes in uptake of flotufolastat F-18 in prostate cancer. Effect on POSLUMA PET performance not established.
Source: NLP:flotufolastat f-18